<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01422226</url>
  </required_header>
  <id_info>
    <org_study_id>10-1060</org_study_id>
    <nct_id>NCT01422226</nct_id>
  </id_info>
  <brief_title>Intra Uterine Device Insertion in Nulliparous Women</brief_title>
  <official_title>IUD Insertion in Nulliparous Women: A Randomized, Placebo-Controlled Trial of Misoprostol for Cervical Priming</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over the last several years, more and more women are choosing intrauterine contraception
      (IUDs) to meet their birth control needs. The effectiveness of IUDs is very similar to tubal
      sterilization, with an overall unintended pregnancy rate of less than 1% in the first year,
      and lower failure rates in subsequent years. Intrauterine contraception has many attributes
      besides its effectiveness; it is easily reversible, has a low side-effect profile, and
      provides a long-term solution for contraception (10 years for the copper T380 and 5 years for
      the levonorgestrel IUD). In addition, using an IUD for birth control requires little on-going
      effort by the woman to be effective and offers immediate return to fertility with its
      removal.

      The biggest increase in users is among nulliparous women (women who have not had children),
      due to increased awareness of the safety of modern IUDs in this population, and the many
      benefits of the method. In fact, The copper IUD (Paragard) is now FDA approved for use in
      nulliparous women, and the American College of Obstetricians and Gynecologists supports the
      use of both copper and levonorgestrel IUDs in nulliparous women. The cervix of a nulliparous
      woman has a smaller diameter which can lead to more difficult and uncomfortable IUD
      insertions. Many providers avoid offering IUDs to nulliparas because of fears that the
      procedure will be more difficult, and may require cervical dilation, placement of a
      paracervical nerve block, or placement under ultrasound guidance, none of which are standard
      for parous women. The medication misoprostol is a prostaglandin E1 analog. Because of
      misoprostol's known ability to cause cervical dilation, some family planning providers give
      their nulliparous patients a dose of this drug prior to IUD insertion. Misoprostol is
      commonly used to dilate the cervix for similar procedures as in first trimester abortions,
      hysteroscopy and endometrial biopsies. Its efficacy in cervical priming for IUD insertion is
      unknown, and some concern exists that uterine contractions caused by the drug may lead to
      device expulsion or displacement.

      In this study, the investigators propose to ask nulliparous women who have undergone
      contraceptive counseling and decided to use an IUD for birth control to be randomized to the
      use of misoprostol or placebo prior to their scheduled IUD placement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: The prostaglandin E1 analog misoprostol will ease insertion of intrauterine
      contraceptive devices in nulliparous women.

      Specific Aim 1: To evaluate the ability to place an IUD in the standard fashion, without
      ancillary measures, in nulliparous women who have received misoprostol versus placebo
      Specific Aim 2: To evaluate in nulliparous women who have chosen to receive an IUD whether
      pre-procedure misoprostol eases pain, compared to placebo Specific Aim 3: To evaluate whether
      misoprostol reduces the rate of complications of IUD placement, compared to placebo Study
      drug (misoprostol) is being obtained from the University of Utah Health Sciences Center,
      which is the main study site. The University of Utah Health Sciences Center has obtained an
      Investigational New Drug (IND) exemption from the FDA in order to use misoprostol for this
      use in this study. This study is part of a prospective meta-analysis. Deidentified data will
      be provided to the other sites in a password protected spreadsheet and sent via encrypted,
      secure email. No identifiable data will be shared with other sites or via the internet. We
      did not complete attachment G, use of the internet, because this research is not being done
      via the internet, and no identifiable data will be accessible via the internet or shared with
      other sites involved in the study. Only deidentified data will be made available to the other
      sites involved in the prospective meta-analysis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to recruit participants
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ease of IUD Insertion (Use of Ancillary Measures)</measure>
    <time_frame>During the IUD insertion procedure, up to 2 hours</time_frame>
    <description>The primary outcome is the proportion in each group able to have the IUD inserted in a standard fashion without the ancillary measures of mechanical dilation of the cervix, placement of paracervical nerve block, or using abdominal ultrasound for guidance. The null hypothesis for the primary outcome is that misoprostol does not influence difficulty of insertion.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Experimental active comparator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Misoprostol
Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Other: Placebo
Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion</description>
    <arm_group_label>Experimental active comparator</arm_group_label>
    <other_name>synthetic prostaglandin E1 (PGE1) analog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion</description>
    <arm_group_label>Placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Desires IUD placement

          -  18 years old or older

          -  negative pregnancy test

          -  no prior pregnancies beyond 14 6/7 weeks

          -  no pelvic inflammatory disease (PID) in last 3 months

          -  no current cervicitis

          -  no contraindications to IUD insertion (see exclusion criteria below)

          -  willing to follow-up in 6-8 weeks for a standard IUD follow-up visit

          -  Determined by her clinician to be an appropriate candidate for an IUD.

        Exclusion Criteria:

          -  Active cervical infection

          -  current pregnancy

          -  prior pregnancy beyond 15 weeks' gestation

          -  uterine anomaly

          -  fibroid uterus

          -  copper allergy/Wilson's disease (for Paragard)

          -  undiagnosed abnormal uterine bleeding

          -  cervical or uterine cancer

          -  allergy to misoprostol (study drug)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Teal, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Hopspital, The Children's Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ghersi D. Prospective Meta-Analysis Methods Group. The Cochrane Collaboration 2002 [cited July 2, 2008]; Available from: http://www.cochrane.org/docs/pma.htm</citation>
  </reference>
  <reference>
    <citation>Sääv I, Aronsson A, Marions L, Stephansson O, Gemzell-Danielsson K. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod. 2007 Oct;22(10):2647-52. Epub 2007 Jul 25.</citation>
    <PMID>17652452</PMID>
  </reference>
  <reference>
    <citation>Crane JM, Healey S. Use of misoprostol before hysteroscopy: a systematic review. J Obstet Gynaecol Can. 2006 May;28(5):373-9. Review.</citation>
    <PMID>16768880</PMID>
  </reference>
  <reference>
    <citation>Carbonell JL, Velazco A, Rodriguez Y, Tanda R, Sánchez C, Barambio S, Valera L, Chami S, Valero F, Aragón S, Marí J. Oral versus vaginal misoprostol for cervical priming in first-trimester abortion: a randomized trial. Eur J Contracept Reprod Health Care. 2001 Sep;6(3):134-40.</citation>
    <PMID>11763976</PMID>
  </reference>
  <reference>
    <citation>Tang OS, Ho PC. The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion. Contraception. 2006 Jul;74(1):26-30. Epub 2006 Apr 27. Review.</citation>
    <PMID>16781256</PMID>
  </reference>
  <reference>
    <citation>Allen RH, Goldberg AB; Board of Society of Family Planning. Cervical dilation before first-trimester surgical abortion (&lt;14 weeks' gestation). SFP Guideline 20071. Contraception. 2007 Aug;76(2):139-56. Epub 2007 Jul 10.</citation>
    <PMID>17656184</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 392, December 2007. Intrauterine device and adolescents. Obstet Gynecol. 2007 Dec;110(6):1493-5.</citation>
    <PMID>18055754</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 59, January 2005. Intrauterine device. Obstet Gynecol. 2005 Jan;105(1):223-32.</citation>
    <PMID>15625179</PMID>
  </reference>
  <reference>
    <citation>Trussell J. Contraceptive failure in the United States. Contraception. 2004 Aug;70(2):89-96. Review.</citation>
    <PMID>15288211</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2011</study_first_submitted>
  <study_first_submitted_qc>August 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2011</study_first_posted>
  <results_first_submitted>February 11, 2015</results_first_submitted>
  <results_first_submitted_qc>February 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2015</results_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IUD</keyword>
  <keyword>contraception</keyword>
  <keyword>nulliparous</keyword>
  <keyword>women</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental Active Comparator</title>
          <description>Misoprostol: Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion</description>
        </group>
        <group group_id="P2">
          <title>Placebo Comparator</title>
          <description>Placebo: Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental Active Comparator</title>
          <description>Misoprostol: Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion</description>
        </group>
        <group group_id="B2">
          <title>Placebo Comparator</title>
          <description>Placebo: Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ease of IUD Insertion (Use of Ancillary Measures)</title>
        <description>The primary outcome is the proportion in each group able to have the IUD inserted in a standard fashion without the ancillary measures of mechanical dilation of the cervix, placement of paracervical nerve block, or using abdominal ultrasound for guidance. The null hypothesis for the primary outcome is that misoprostol does not influence difficulty of insertion.</description>
        <time_frame>During the IUD insertion procedure, up to 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Active Comparator</title>
            <description>Misoprostol: Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Placebo: Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion</description>
          </group>
        </group_list>
        <measure>
          <title>Ease of IUD Insertion (Use of Ancillary Measures)</title>
          <description>The primary outcome is the proportion in each group able to have the IUD inserted in a standard fashion without the ancillary measures of mechanical dilation of the cervix, placement of paracervical nerve block, or using abdominal ultrasound for guidance. The null hypothesis for the primary outcome is that misoprostol does not influence difficulty of insertion.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental Active Comparator</title>
          <description>Misoprostol: Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion</description>
        </group>
        <group group_id="E2">
          <title>Placebo Comparator</title>
          <description>Placebo: Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christina Gavito</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>303-724-5559</phone>
      <email>christina.gavito@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

